CRISPR Therapeutics (NASDAQ:CRSP) Director Kurt Von Emster sold 250,000 shares of the business’s stock in a transaction that occurred on Friday, May 11th. The stock was sold at an average price of $52.84, for a total transaction of $13,210,000.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Kurt Von Emster also recently made the following trade(s):
- On Monday, May 14th, Kurt Von Emster sold 650,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $54.39, for a total transaction of $35,353,500.00.
CRISPR Therapeutics stock traded up $0.97 during mid-day trading on Tuesday, reaching $57.75. 2,269,551 shares of the company traded hands, compared to its average volume of 1,180,944. CRISPR Therapeutics has a fifty-two week low of $54.08 and a fifty-two week high of $59.85. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of -33.77 and a beta of 3.58.
CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.05. CRISPR Therapeutics had a negative net margin of 189.60% and a negative return on equity of 35.18%. The business had revenue of $1.36 million for the quarter, compared to analyst estimates of $3.64 million. During the same quarter in the prior year, the business posted ($0.54) EPS. CRISPR Therapeutics’s revenue for the quarter was down 49.6% compared to the same quarter last year. equities research analysts anticipate that CRISPR Therapeutics will post -2.6 EPS for the current fiscal year.
A number of institutional investors have recently modified their holdings of the business. Hilltop Holdings Inc. acquired a new position in CRISPR Therapeutics during the 1st quarter valued at approximately $919,000. LPL Financial LLC acquired a new position in CRISPR Therapeutics during the 1st quarter valued at approximately $256,000. Ladenburg Thalmann Financial Services Inc. increased its stake in CRISPR Therapeutics by 334.0% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,054 shares of the company’s stock valued at $186,000 after purchasing an additional 3,120 shares in the last quarter. Jane Street Group LLC acquired a new position in CRISPR Therapeutics during the 1st quarter valued at approximately $886,000. Finally, Element Capital Management LLC acquired a new position in CRISPR Therapeutics during the 1st quarter valued at approximately $210,000. Institutional investors and hedge funds own 36.73% of the company’s stock.
Several research analysts recently commented on the stock. Chardan Capital boosted their price objective on shares of CRISPR Therapeutics from $25.00 to $72.50 and gave the stock a “buy” rating in a research note on Tuesday. TheStreet lowered shares of CRISPR Therapeutics from a “c” rating to a “d+” rating in a research note on Friday. BidaskClub upgraded shares of CRISPR Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Monday. Zacks Investment Research upgraded shares of CRISPR Therapeutics from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Friday. Finally, Goldman Sachs assumed coverage on shares of CRISPR Therapeutics in a research note on Friday, April 6th. They set a “buy” rating and a $86.00 price objective for the company. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $64.28.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.